Insilico partners with Taisho Pharmaceutical on end-to-end AI-powered senolytic drug discovery. Leading Japanese pharmaceutical company to engage Insilico Medicine on research partnership in the ...

Activist fund Oasis Management is considering legal action over Taisho Pharmaceutical's $5 billion management buyout - Japan's largest to date - arguing that it was deeply unfair to minority ...

Taisho Pharmaceutical Holdings Co. is nearing a deal to buy Bristol-Myers Squibb Co.’s French over-the-counter unit, people familiar with the matter said, as the Japanese drugmaker seeks to ...

Oasis Management, a Hong Kong-based activist fund, said it is opposed to Taisho Pharmaceutical's $5 billion management buyout as it believes the acquisition price was too low.

H eadquartered in Millennium Centennial Center in central Jakarta, Taisho Pharmaceutical Indonesia is playing an important role within Indonesia’s health care sector.. Japan’s Taisho ...

TOKYO -- Investment funds Curi RMB Capital and Oasis Management are contesting the pricing of Taisho Pharmaceutical Holdings' management buyout in court, Nikkei has learned, after failed ...

Contacts. Teva Pharmaceutical Industries Ltd. Elana Holzman, 972 (3) 926-7554 or Teva North America Kevin Mannix, 215-591-8912 ...

Japan-based Taisho Pharmaceutical has registered to purchase an additional of nearly 1 million shares in Vietnam’s DHG Pharmaceutical, lifting its holding in the latter to nearly 35%, according to a ...

Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk JAKARTA, ...

“Taisho’s profound commitment to improving health has been a cornerstone of its success for over 100 years, and we are thrilled to have them as our first commercial partner,” said Jared ...

Curi RMB Capital believes the intrinsic value of Taisho should be no less than 10,132 yen per share, which is Taisho's book value per share as of September 30th, 2023. Curi RMB Capital believes the ...

Pfizer and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B.